Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway

Authors: Tao Jia, Li Zhang, Yale Duan, Min Zhang, Gang Wang, Jun Zhang, Zheng Zhao

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

The mechanism underlying the differential cytotoxicity of curcumin in various cancer types, however, remains largely unclear. The aims of this study is to examine the concentration- and time-related effects of curcumin on two different breast cancer cells, MCF-7 and MDA-MB-231, and investigated the functional changes induced by curcumin treatment, as well as their relationship to the PI3K/Akt-SKP2-Cip/Kips pathway.

Methods

First, WST-1 and clonogenic assay were performed to determine the cytotoxicity of curcumin in MCF-7 and MDA-MB-231 cells. Then, the expression of CDK interacting protein/Kinase inhibitory protein (Cip/Kips) members (p27, p21 and p57) and S-phase kinase-associated protein-2 (SKP2) was investigated by QRT PCR and Western Blotting. Curcumin’s effect on PI3K (phosphatidylinositol 3-kinase) /Akt and its substrates Foxo1 and Foxo3a were then studied by Western Blotting. Small interfering RNAs (siRNAs) targeting SKP2 was used to explore the relationship between SKP2 and Cip/Kips members. Finally, WST-1 assay was tested to explore the concomitant treatment with curcumin and the inhibition of PKB or SKP2 signaling on curcumin sensitivity in MCF-7 and MDA-MB-231 cells.

Results

We demonstrated MCF-7 and MDA-MB-231 cells exhibited differential responses to curcumin by WST-1 and clonogenic assay (MDA-MB-231 cells was sensitive, and MCF-7 cells was resistant), which were found to be related to the differential curcumin-mediated regulation of SKP2-Cip/Kips (p21 and p27 but not p57) signaling. The differential cellular responses were further linked to the converse effects of curcumin on PI3K/Akt and its substrates Foxo1 and Foxo3a. Importantly, PI3K inhibitor wortmannin could counteract both curcumin-induced phosphorylation of Akt and up-regulation of SKP2 in MCF-7 cells. Subsequent WST-1 assay demonstrated concomitant treatment with curcumin and wortmannin or SKP2 siRNA not only further augmented curcumin sensitivity in MDA-MB-231 cells but also overcame curcumin resistance in MCF-7 cells.

Conclusions

Our study established PI3K/Akt-SKP2-Cip/Kips signaling pathway is involved in the mechanism of action of curcumin and revealed that the discrepant modulation of this pathway by curcumin is responsible for the differential susceptibilities of these two cell types to curcumin.
Appendix
Available only for authorised users
Literature
1.
Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA: Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A. 2012, 109: 2724-2729. 10.1073/pnas.1018854108.CrossRefPubMedCentralPubMed
2.
Commandeur JN, Vermeulen NP: Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica. 1996, 26: 667-680. 10.3109/00498259609046741.CrossRefPubMed
3.
Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008, 52 (Suppl 1): S103-S127.PubMed
4.
Goel A, Kunnumakkara AB, Aggarwal BB: Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008, 75: 787-809. 10.1016/j.bcp.2007.08.016.CrossRefPubMed
5.
Mehta K, Pantazis P, McQueen T, Aggarwal BB: Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs. 1997, 8: 470-481. 10.1097/00001813-199706000-00010.CrossRefPubMed
6.
Teiten MH, Eifes S, Dicato M, Diederich M: Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel). 2010, 2: 128-162. 10.3390/toxins2010128.CrossRef
7.
Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ: Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002, 62: 3868-3875.PubMed
8.
Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro M: The dark side of curcumin. Int J Cancer. 2010, 126: 1771-1775.PubMed
9.
Russo M, Spagnuolo C, Tedesco I, Russo GL: Phytochemicals in cancer prevention and therapy: truth or dare?. Toxins (Basel). 2010, 2: 517-551. 10.3390/toxins2040517.CrossRef
10.
Denicourt C, Dowdy SF: Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 2004, 18: 851-855. 10.1101/gad.1205304.CrossRefPubMed
11.
Lim S, Kaldis P: Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013, 140: 3079-3093. 10.1242/dev.091744.CrossRefPubMed
12.
Sun Y: Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther. 2003, 2: 623-629.PubMed
13.
Nakayama KI, Nakayama K: Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol. 2005, 16: 323-333. 10.1016/j.semcdb.2005.02.010.CrossRefPubMed
14.
Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R: Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006, 99: 185-191. 10.1007/s10549-006-9202-3.CrossRefPubMed
15.
Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M: Significance of skp2 expression in primary breast cancer. Clin Cancer Res. 2006, 12: 1215-1220. 10.1158/1078-0432.CCR-05-1709.CrossRefPubMed
16.
Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W: Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 2012, 1: 18702-18712. 10.3389/fonc.2011.00057.CrossRefPubMed
17.
Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK: Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013, 154: 556-568. 10.1016/j.cell.2013.06.048.CrossRefPubMed
18.
Hershko DD: Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 2008, 112: 1415-1424. 10.1002/cncr.23317.CrossRefPubMed
19.
Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P, Pandolfi PP: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009, 11: 420-432. 10.1038/ncb1849.CrossRefPubMedCentralPubMed
20.
Gao DM, Inuzuka H, Tseng A, Chin RY, Toker A, Wei WY: Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APC-Cdh1-mediated Skp2 destruction. Nat Cell Biol. 2009, 11: 397-408. 10.1038/ncb1847.CrossRefPubMedCentralPubMed
21.
Bashir T, Pagan JK, Busino L, Pagano M: Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization. Cell Cycle. 2010, 9: 971-974. 10.4161/cc.9.5.10914.CrossRefPubMedCentralPubMed
22.
Boutonnet C, Tanguay PL, Julien C, Rodier G, Coulombe P, Meloche S: Phosphorylation of Ser72 does not regulate the ubiquitin ligase activity and subcellular localization of Skp2. Cell Cycle. 2010, 9: 975-979. 10.4161/cc.9.5.10915.CrossRefPubMed
23.
Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK: The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. Cell. 2012, 149: 1098-1111. 10.1016/j.cell.2012.02.065.CrossRefPubMedCentralPubMed
24.
Huang HC, Way TD, Lin CL, Lin JK: EGCG Stabilizes p27(kip1) in E2-Stimulated MCF-7 Cells through Down-Regulation of the Skp2 Protein. Endocrinology. 2008, 149: 5972-5983. 10.1210/en.2008-0408.CrossRefPubMed
25.
Dillon RL, Muller WJ: Distinct biological roles for the akt family in mammary tumor progression. Cancer Res. 2010, 70: 4260-4264. 10.1158/0008-5472.CAN-10-0266.CrossRefPubMedCentralPubMed
26.
27.
Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM: Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A. 2000, 97: 9042-9046. 10.1073/pnas.160016897.CrossRefPubMedCentralPubMed
28.
Tchernev G, Orfanos CE: Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol. 2007, 34: 247-256. 10.1111/j.1600-0560.2006.00700.x.CrossRefPubMed
29.
Schmidt M, Fan Z: Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene. 2001, 20: 6164-6171. 10.1038/sj.onc.1204814.CrossRefPubMed
30.
Shrotriya S, Deep G, Ramasamy K, Raina K, Barbakadze V, Merlani M, Gogilashvili L, Amiranashvili L, Mulkijanyan K, Papadopoulos K, Agarwal C, Agarwal R: Poly[3-(3, 4-dihydroxyphenyl) glyceric] acid from Comfrey exerts anti-cancer efficacy against human prostate cancer via targeting androgen receptor, cell cycle arrest and apoptosis. Carcinogenesis. 2012, 33: 1572-1580. 10.1093/carcin/bgs019.CrossRefPubMed
31.
Vaid M, Sharma SD, Katiyar SK: Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation. Carcinogenesis. 2010, 31: 2004-2011. 10.1093/carcin/bgq186.CrossRefPubMed
32.
Kim KC, Lee C: Curcumin induces downregulation of E2F4 expression and apoptotic cell death in HCT116 human colon cancer cells; involvement of reactive oxygen species. Korean J Physiol Pharmacol. 2010, 14: 391-397. 10.4196/kjpp.2010.14.6.391.CrossRefPubMedCentralPubMed
33.
Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharm. 2007, 73: 1024-1032. 10.1016/j.bcp.2006.12.010.CrossRefPubMed
34.
Chiu TL, Su CC: Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappa Bp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 2009, 23: 469-475.PubMed
35.
Shao ZM, Shen ZZ, Liu CH, Sartippour MR, Go VL, Heber D, Nguyen M: Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer. 2002, 98: 234-240. 10.1002/ijc.10183.CrossRefPubMed
36.
Harada K, Supriatno , Kawashima Y, Itashiki Y, Yoshida H, Sato M: Down-regulation of S-phase kinase associated protein 2 (Skp2) induces apoptosis in oral cancer cells. Oral Oncol. 2005, 41: 623-630. 10.1016/j.oraloncology.2005.02.007.CrossRefPubMed
37.
Yokoi S, Yasui K, Iizasa T, Takahashi T, Fujisawa T, Inazawa J: Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci. 2003, 94: 344-349. 10.1111/j.1349-7006.2003.tb01444.x.CrossRefPubMed
38.
Sun L, Cai L, Yu Y, Meng Q, Cheng X, Zhao Y, Sui G, Zhang F: Knockdown of S-phase kinase-associated protein-2 expression in MCF-7 inhibits cell growth and enhances the cytotoxic effects of epirubicin. Acta Biochim Biophys Sin (Shanghai). 2007, 39: 999-1007. 10.1111/j.1745-7270.2007.00361.x.CrossRef
39.
Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR: Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res. 2012, 72: 1836-1843. 10.1158/0008-5472.CAN-11-2195.CrossRefPubMedCentralPubMed
40.
Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M: Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002, 110: 633-641. 10.1172/JCI0215795.CrossRefPubMedCentralPubMed
41.
Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, Hatakeyama S, Nakayama K, Nakayama KI: Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003, 100: 10231-10236. 10.1073/pnas.1831009100.CrossRefPubMedCentralPubMed
42.
Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 2012, 17: 69-95. 10.1615/CritRevOncog.v17.i1.60.CrossRefPubMed
43.
Liang J, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003, 2: 339-345. 10.4161/cc.2.4.433.CrossRefPubMed
44.
Cox BD, Natarajan M, Stettner MR, Gladson CL: New concepts regarding focal promotion of cell migration adhesion kinase and proliferation. J Cell Biochem. 2006, 99: 36-52. 10.1002/jcb.20956.CrossRef
45.
Bryant P, Zheng Q, Pumiglia K: Focal adhesion kinase controls cellular levels of p27/Kip1 and p21/Cip1 through Skp2-dependent and -independent mechanisms. Mol Cell Biol. 2006, 26: 4201-4213. 10.1128/MCB.01612-05.CrossRefPubMedCentralPubMed
46.
Shapira M, Kakiashvili E, Rosenberg T, Hershko DD: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006, 8: R46-10.1186/bcr1533.CrossRefPubMedCentralPubMed
47.
Reagan-Shaw S, Ahmad N: RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res. 2006, 66: 1062-1069. 10.1158/0008-5472.CAN-05-1018.CrossRefPubMed
48.
Reagan-Shaw S, Ahmad N: The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol. 2007, 224: 360-368. 10.1016/j.taap.2006.12.003.CrossRefPubMed
49.
Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME: Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001, 21: 952-965. 10.1128/MCB.21.3.952-965.2001.CrossRefPubMedCentralPubMed
50.
Wu YY, Shang XY, Sarkissyan M, Slamon D, Vadgama JV: FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010, 70: 5475-5485. 10.1158/0008-5472.CAN-10-0176.CrossRefPubMedCentralPubMed
Metadata
Title
The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway
Authors
Tao Jia
Li Zhang
Yale Duan
Min Zhang
Gang Wang
Jun Zhang
Zheng Zhao
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-014-0126-4

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue

Review

The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance

Reviewer acknowledgement

Thanking Cancer Cell International’s 2013 reviewers

Primary research

The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients

Primary research

Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro

Primary research

The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation

Primary research

Human umbilical cord mesenchymal stem cells promote carcinoma growth and lymph node metastasis when co-injected with esophageal carcinoma cells in nude mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits